Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Agenus Inc.

< Previous 1 2 Next >
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in B. Riley Healthcare Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Third Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
From Agenus Inc.
Via Business Wire
Tickers AGEN
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus To Host BOT/BAL Program Update at ESMO 2023
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Second Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Expands Executive Leadership Team
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
Tickers AGEN INKT
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Participate in February Investor Conferences
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.